Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase I, Double-Blinded, Parallel Comparative Assessment of PK, PD, Safety, and Immunogenicity of BP11 Versus US-Licensed Xolair® and EU Approved-Xolair® Following a Single 150 mg Dose SC Administration in Healthy Male Volunteers

NCT05053334 is registered in ClinicalTrials.gov with Syneos Health as lead sponsor.

NCT NCT05053334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05053334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase I, Double-Blinded, Parallel Comparative Assessment of PK, PD, Safety, and Immunogenicity of BP11 Versus US-Licensed Xolair® and EU Approved-Xolair® Following a Single 150 mg Dose SC Administration in Healthy Male Volunteers
Lead sponsor
Syneos Health
Phase
Phase 1
Overall status
Completed
Start date
February 16, 2022
Completion date
January 10, 2024
Enrollment
165 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers